
eTheRNA research agreement with Merck to access mRNA technologies
eTheRNA immunotherapies has partnered with Merck to investigate the application of eTheRNA’s mRNA design expertise and LNP-delivery platforms to disease areas selected by Merck. Context The ongoing pandemic has underlined the capability for mRNA vaccines as a new therapeutic modality. eTheRNA and Merck both recognise… Read More















